GlassScriptPhysician profile
Suhail Masudi
NPI 1649206525
$8,343.82
in general payments reported to CMS, 2019-2025
43 companies · $432 in 2025
The $432 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,960 · 2020: $1,678 · 2021: $1,463 · 2022: $1,266 · 2023: $762 · 2024: $783 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.82 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,286.42 | 2019-2024 | |
| Novo Nordisk INC | $1,159.24 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $793.27 | 2019-2024 | Jardiance, Mounjaro, Lyumjev |
| Astrazeneca Pharmaceuticals LP | $667.99 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $561.39 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $447.63 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $331.86 | 2020-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $323.15 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $304.52 | 2019-2025 | Unithroid |
| Dexcom, INC. | $282.64 | 2023-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $280.52 | 2019-2025 | Afrezza |
| Antares Pharma, INC. | $223.19 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Abbott Laboratories | $202.69 | 2020-2025 | Freestyle Libre 3 |
| Abbvie INC. | $188.69 | 2019-2024 | |
| Corcept Therapeutics | $146.10 | 2020-2025 | Korlym |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suhail Masudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.